Recent Updates
Recently added Catalysts
NMRA Positive Sentiment

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

Key Takeaway: Neumora Therapeutics will participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company aims to redefine neuroscience drug development with its innovative therapeutic pipeline. A live webcast of the event will be available on their website, with a replay accessible for 30 days post-event.
Price reaction · baseline $1.9 (2026-05-12 close) · hit pre-market · clean, no other NMRA news in the window
day 0 close
-6.3%
day 1
+3.7%
day 3 · peak
-6.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Neumora Therapeutics is participating in a prominent healthcare conference.
  • The company is focused on developing innovative treatments for brain diseases.
  • Their therapeutic pipeline targets underserved diseases, indicating a strong mission.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
6.5%
average across 6 past catalysts
Cash runway
~9 mo
High dilution risk
Lead asset
NMRA-335140
Phase 3 · Major Depressive Disorder

Full Press Release Details

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) --Neumora Therapeutics, Inc.(Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m. ET.
A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website atwww.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About NeumoraNeumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Frequently Asked Questions

When will Neumora participate in the conference?

Neumora will participate in the conference on May 19, 2026.

What is the focus of Neumora Therapeutics?

Neumora focuses on developing treatments for brain diseases.

How can I watch the conference live?

A live webcast will be available on Neumora's website during the event.

Will there be a replay of the event?

Yes, a replay will be available for 30 days after the event.

Last updated: May 13, 2026